Switch theme
Sign up to access all valuation multiples
Neuland Laboratories Ltd is a manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs in Hyderabad. Geographically, it derives a majority of revenue from North America and also has a presence in India, Europe, and Rest of the world.
1984
1.6K+
LTM Revenue $181M
LTM EBITDA $46.0M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Neuland Laboratories has a last 12-month revenue of $181M and a last 12-month EBITDA of $46.0M.
In the most recent fiscal year, Neuland Laboratories achieved revenue of $176M and an EBITDA of $54.8M.
Neuland Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Neuland Laboratories valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $135M | $176M | XXX | XXX | XXX |
| Gross Profit | $43.0M | $63.5M | XXX | XXX | XXX |
| Gross Margin | 32% | 36% | XXX | XXX | XXX |
| EBITDA | $32.2M | $54.8M | XXX | XXX | XXX |
| EBITDA Margin | 24% | 31% | XXX | XXX | XXX |
| Net Profit | $7.4M | $19.0M | XXX | XXX | XXX |
| Net Margin | 5% | 11% | XXX | XXX | XXX |
| Net Debt | $26.2M | $8.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Neuland Laboratories's stock price is INR 11705 (or $136).
Neuland Laboratories has current market cap of INR 150B (or $1.7B), and EV of INR 149B (or $1.7B).
See Neuland Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $1.7B | XXX | XXX | XXX | XXX | $2.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Neuland Laboratories has market cap of $1.7B and EV of $1.7B.
Neuland Laboratories's trades at 9.6x LTM EV/Revenue multiple, and 37.7x LTM EBITDA.
Analysts estimate Neuland Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Neuland Laboratories and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 9.8x | XXX | XXX | XXX |
| EV/EBITDA | 36.7x | XXX | XXX | XXX |
| P/E | 53.4x | XXX | XXX | XXX |
| P/E/Growth | 1.3x | XXX | XXX | XXX |
| EV/FCF | 58.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNeuland Laboratories's NTM/LTM revenue growth is 33%
Neuland Laboratories's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $26K for the same period.
Over next 12 months, Neuland Laboratories's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Neuland Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Neuland Laboratories and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 31% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 71% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 59% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $26K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 25% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Neuland Laboratories acquired XXX companies to date.
Last acquisition by Neuland Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Neuland Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Neuland Laboratories founded? | Neuland Laboratories was founded in 1984. |
| Where is Neuland Laboratories headquartered? | Neuland Laboratories is headquartered in India. |
| How many employees does Neuland Laboratories have? | As of today, Neuland Laboratories has 1.6K+ employees. |
| Who is the CEO of Neuland Laboratories? | Neuland Laboratories's CEO is Mr. Davuluri Sucheth Rao. |
| Is Neuland Laboratories publicy listed? | Yes, Neuland Laboratories is a public company listed on BOM. |
| What is the stock symbol of Neuland Laboratories? | Neuland Laboratories trades under 524558 ticker. |
| When did Neuland Laboratories go public? | Neuland Laboratories went public in 1994. |
| Who are competitors of Neuland Laboratories? | Similar companies to Neuland Laboratories include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Neuland Laboratories? | Neuland Laboratories's current market cap is $1.7B |
| What is the current revenue of Neuland Laboratories? | Neuland Laboratories's last 12-month revenue is $181M. |
| What is the current EBITDA of Neuland Laboratories? | Neuland Laboratories's last 12-month EBITDA is $46.0M. |
| What is the current EV/Revenue multiple of Neuland Laboratories? | Current revenue multiple of Neuland Laboratories is 9.6x. |
| What is the current EV/EBITDA multiple of Neuland Laboratories? | Current EBITDA multiple of Neuland Laboratories is 37.7x. |
| What is the current revenue growth of Neuland Laboratories? | Neuland Laboratories revenue growth between 2023 and 2024 was 31%. |
| Is Neuland Laboratories profitable? | Yes, Neuland Laboratories is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
